Delhi court halts 151 crore recovery from AstraZeneca in drug pricing case

what happened

The Delhi High Court has blocked the National Pharmaceutical Pricing Authority (NPPA) from taking enforcement steps against AstraZeneca Pharma India over more than 151 crore that the regulator says was overcharged on a drug. The order stays in place until the next hearing, scheduled for January 11. Justice Amit Mahajan said the company had made a credible case that its Symbicort Turbuhaler 160/4.5 inhaler may not fall under the category of drugs with controlled prices.

The NPPA says the violations took place between May 2016 and November 2025. The company denies selling the product above its fixed price and argues that its dosage differs from the one listed in the schedule to the 2013 pricing order. According to AstraZeneca, the product was approved for import in this dosage in 2003, and the ceiling price for a similar product was set only in 2019.

why it matters

For markets, the case mainly concerns one company and India's drug price controls. The ruling is interim, so the final outcome depends on the next hearing. It shows how regulatory pricing disputes can affect the revenues of local units of global pharmaceutical firms.

tags

instruments